Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies

Chimeric antigen receptor (CAR) T-cell therapy has shown promising clinical impact against hematologic malignancies. CD19 is a marker on the surface of normal B cells as well as most B-cell malignancies, and thus has a role as an effective target for CAR T-cell therapy. In numerous clinical data, su...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Moo-Kon, Park, Byeong-Bae, Uhm, Ji-Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834308/
https://www.ncbi.nlm.nih.gov/pubmed/31658644
http://dx.doi.org/10.3390/ijms20205010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834308/
https://www.ncbi.nlm.nih.gov/pubmed/31658644
http://dx.doi.org/10.3390/ijms20205010

Ejemplares similares